Clinical Research Papers:
Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1147 views | HTML 1718 views | ?
Abstract
Xiao-Lin Luo1,*, Guang-Zheng Zhong2,*, Li-Yang Hu3,*, Jie Chen4, Ying Liang3, Qiu-Yan Chen5, Qing Liu6, Hui-Lan Rao7, Kai-Lin Chen3, Qing-Qing Cai3
1Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
4Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Radiotherapy Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
5Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
6Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
7Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
*These authors have contributed equally to this work
Correspondence to:
Qing-Qing Cai, e-mail: [email protected]
Keywords: non-metastatic nasopharyngeal carcinoma (NPC), apolipoprotein A-I (ApoA-I), prognosis
Received: May 06, 2015 Accepted: October 09, 2015 Published: October 19, 2015
ABSTRACT
Background: We investigated the value of pretreatment serum apolipoprotein A-I (ApoA-I) in complementing TNM staging in the prognosis of non-metastatic nasopharyngeal carcinoma (NPC).
Patients and methods: We retrospectively reviewed 1196 newly diagnosed patients with non-metastatic NPC. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to serum ApoA-I level. Multivariate analysis was performed to assess the prognostic value of serum ApoA-I.
Results: The 5-year DSS, DMFS, and LRFS rates for patients with elevated or decreased serum ApoA-I were 81.3% versus 69.3% (P < 0.001), 83.4% versus 67.4% (P < 0.001), and 80.9% versus 67.3% (P < 0.001), respectively. ApoA-I ≥ 1.025 g/L was an independent prognostic factor for superior DSS, DMFS, and LRFS in multivariate analysis. After stratification by clinical stage, serum ApoA-I remained a clinically and statistically significant predictor of prognosis.
Conclusion: Our data suggest that the level of ApoA-I at diagnosis is a novel independent prognostic marker that could complement clinical staging for risk definition in non-metastatic NPC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5823